Theriva Biologics, Inc. 8-K

What Happened

• Theriva Biologics (TOVX) filed a Form 8-K on April 17, 2026 to disclose a press release and an upcoming poster presentation at the AACR Annual Meeting (San Diego, April 17–22, 2026).
• The poster (CT162) titled “Analysis of tumor and biomarker responses in the VIRAGE Trial” will be presented by Dr. Manuel Hidalgo on Monday, April 20, 2026 (2:00–5:00 PM PDT) in session PO.CT01.05. The poster analyzes randomized Phase 2b VIRAGE results for VCN-01 (zabilugene almadenorepvec) given with gemcitabine/nab‑paclitaxel (GnP) vs GnP alone in newly diagnosed metastatic pancreatic cancer.

Key Details

• Presentation: Poster # CT162, April 20, 2026, 2:00–5:00 PM PDT; Presenter: Dr. Manuel Hidalgo (NYU Langone Perlmutter Cancer Center).
• Main findings reported in the poster: VCN-01 + GnP showed improved overall survival (OS) and progression‑free survival (PFS) versus GnP alone; responses were later‑emerging, higher in magnitude, and more durable.
• Subgroup note: OS benefit was generally maintained across subgroups, including patients with liver metastases, despite a post‑recruitment imbalance.
• Additional signal: Patients receiving a second administration of VCN‑01 showed greater OS and PFS benefit. The full poster was released by AACR and filed as Exhibit 99.2 to the 8‑K.

Why It Matters

• For investors, the disclosed Phase 2b signals (improved OS and PFS, durable responses, subgroup maintenance) are material clinical development updates about Theriva’s lead program, VCN‑01, and may influence the company’s development path, partner interest, and market perception.
• The company publicly released this information under Regulation FD via the 8‑K; the poster itself is available from AACR and is attached to the filing for review.